American Research & Management Company’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $3.9M | Sell |
51,290
-312
| -0.6% | -$25.9K | 1.08% | 29 |
|
|
2022
Q2 | $4.36M | Sell |
51,602
-816
| -2% | -$71.6K | 1.12% | 27 |
|
|
2022
Q1 | $4.6M | Sell |
52,418
-2,542
| -5% | -$220K | 1.01% | 30 |
|
|
2021
Q4 | $4.81M | Sell |
54,960
-150
| -0.3% | -$12.5K | 1.04% | 28 |
|
|
2021
Q3 | $4.51M | Sell |
55,110
-575
| -1% | -$51.7K | 1.04% | 29 |
|
|
2021
Q2 | $5.08M | Buy |
55,685
+216
| +0.4% | +$19.2K | 1.16% | 29 |
|
|
2021
Q1 | $4.74M | Sell |
55,469
-962
| -2% | -$86.3K | 1.14% | 29 |
|
|
2020
Q4 | $5.33M | Sell |
56,431
-50
| -0.1% | -$4.37K | 1.39% | 25 |
|
|
2020
Q3 | $4.91M | Sell |
56,481
-100
| -0.2% | -$8.66K | 1.43% | 23 |
|
|
2020
Q2 | $4.94M | Sell |
56,581
-493
| -0.9% | -$42.6K | 1.5% | 23 |
|
|
2020
Q1 | $4.71M | Sell |
57,074
-1,573
| -3% | -$140K | 1.79% | 18 |
|
|
2019
Q4 | $5.55M | Sell |
58,647
-950
| -2% | -$85.2K | 1.64% | 18 |
|
|
2019
Q3 | $5.18M | Sell |
59,597
-230
| -0.4% | -$20.7K | 1.56% | 18 |
|
|
2019
Q2 | $5.46M | Sell |
59,827
-7,810
| -12% | -$661K | 1.63% | 19 |
|
|
2019
Q1 | $5.83M | Buy |
67,637
+1,494
| +2% | +$120K | 1.66% | 18 |
|
|
2018
Q4 | $5.09M | Buy |
66,143
+312
| +0.5% | +$24.3K | 1.71% | 18 |
|
|
2018
Q3 | $5.08M | Buy |
65,831
+1,383
| +2% | +$102K | 1.51% | 20 |
|
|
2018
Q2 | $4.36M | Buy |
64,448
+698
| +1% | +$48.2K | 1.52% | 20 |
|
|
2018
Q1 | $4.62M | Sell |
63,750
-921
| -1% | -$70.1K | 1.52% | 20 |
|
|
2017
Q4 | $4.87M | Sell |
64,671
-502
| -0.8% | -$37.9K | 1.5% | 21 |
|
|
2017
Q3 | $5.01M | Hold |
65,173
| – | – | 1.62% | 19 |
|
|
2017
Q2 | $4.88M | Sell |
65,173
-168
| -0.3% | -$11.9K | 1.6% | 21 |
|
|
2017
Q1 | $4.35M | Sell |
65,341
-334
| -0.5% | -$22.3K | 1.55% | 23 |
|
|
2016
Q4 | $4.29M | Sell |
65,675
-3,443
| -5% | -$223K | 1.47% | 23 |
|
|
2016
Q3 | $4.89M | Buy |
69,118
+978
| +1% | +$71.3K | 1.78% | 16 |
|
|
2016
Q2 | $5.04M | Sell |
68,140
-782
| -1% | -$54K | 1.94% | 15 |
|
|
2016
Q1 | $4.47M | Buy |
68,922
+113
| +0.2% | +$7.69K | 1.88% | 17 |
|
|
2015
Q4 | $5.3M | Sell |
68,809
-1,247
| -2% | -$99.1K | 2.27% | 12 |
|
|
2015
Q3 | $5.77M | Buy |
70,056
+216
| +0.3% | +$19.2K | 2.52% | 10 |
|
|
2015
Q2 | $6.15M | Buy |
69,840
+132
| +0.2% | +$12.1K | 2.5% | 10 |
|
|
2015
Q1 | $6.16M | Sell |
69,708
-500
| -0.7% | -$44.4K | 2.51% | 8 |
|
|
2014
Q4 | $5.83M | Sell |
70,208
-55
| -0.1% | -$4.56K | 2.15% | 12 |
|
|
2014
Q3 | $5.93M | Sell |
70,263
-1,258
| -2% | -$102K | 2.14% | 11 |
|
|
2014
Q2 | $5.8M | Sell |
71,521
-636
| -0.9% | -$50K | 2.02% | 10 |
|
|
2014
Q1 | $5.5M | Sell |
72,157
-1,163
| -2% | -$84.7K | 1.96% | 10 |
|
|
2013
Q4 | $5.28M | Sell |
73,320
-262
| -0.4% | -$18.2K | 1.88% | 12 |
|
|
2013
Q3 | $5.06M | Sell |
73,582
-336
| -0.5% | -$22.2K | 2% | 11 |
|
|
2013
Q2 | $4.68M | Buy |
+73,918
| New | +$4.81M | 1.88% | 15 |
|
Other funds holding NVS
CCM
American Research & Management Company's NVS Position: Q3 2022 in Review
American Research & Management Company reduced its Novartis (NVS) stake by 0.6% in Q3 2022, selling an estimated $25.9K and leaving 51,290 shares worth $3.9M. The position accounts for 1.08% of the portfolio, ranked #29.
American Research & Management Company first reported a position in NVS in Q2 2013 and has held it in 38 quarters since. The position peaked at $6.16M in Q1 2015. 1,088 funds tracked by Wall St. Rank hold NVS as of Q3 2022.
- American Research & Management Company held 51,290 shares of Novartis worth $3.9M as of Q3 2022.
- American Research & Management Company sold 312 Novartis shares in Q3 2022, an estimated $25.9K.
- Novartis made up 1.08% of American Research & Management Company's portfolio in Q3 2022, its #29 holding.
- American Research & Management Company first reported a position in Novartis in Q2 2013 and has held it in 38 quarters since.
- American Research & Management Company's Novartis position peaked at $6.16M in Q1 2015.
- 1,088 funds tracked by Wall St. Rank held Novartis as of Q3 2022.
Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.